<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K -- CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported) February 9, 1995
INTERNATIONAL RESEARCH AND DEVELOPMENT CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware 0-7059 38-1688261
(State or other Commission File (I.R.S. Employer
jurisdiction of Number Identification No.)
incorporation or
organization)
500 North Main Street, Mattawan Michigan 49071
(Address of principal executive offices) (Zip Code)
(616) 668-3336
Registrant's telephone number, including area code
Not Applicable
(Former name, former address and former fiscal year,
if changed since last report.)
<PAGE>
Item 5. Other Events.
On February 9, 1995, the registrant issued a press release,
a copy of which is attached as Exhibit 99.2 to this Form 8-K and
incorporated herein by reference.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
Exhibit Number Description
99.2 Press release dated February 9,
1995 issued by the registrant
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
INTERNATIONAL RESEARCH AND
DEVELOPMENT CORPORATION
(Registrant)
Date: February 13, 1995
/s/ Curt Dally
_____________________________
Curt Dally
Secretary and Treasurer
EXHIBIT 99.2
PRESS RELEASE For Release on February 9, 1995
For More Information, Call:
Dr. Francis X. Wazeter,
Chief Executive Officer and
Chairman of the Board
International Research and Development Corporation ("IRDC")
announced today that is seeking offers for the sale of its Carme,
Inc. subsidiary in Novato, California. Carme is engaged in the
manufacture and sale of specialty skin care products. The Board
of Directors has determined to focus IRDC's efforts on its core
business, being the performance of safety evaluation studies of
drugs and their components.
Mesirow Financial, Inc. (Patrick Goy, Senior Vice President or
William Hornell, Senior Vice President - 312-670-6180) has been
named exclusive financial advisor in connection with the sale of
Carme.
IRDC is engaged in the safety evaluation of pharmaceutical and
veterinary drugs, agricultural products, and chemicals. Studies
are performed on behalf of various manufacturers of such
products, both foreign and domestic, and on behalf of
governmental agencies. Clinical safety evaluation studies are
conducted on behalf of clients in the pharmaceutical, chemical
and cosmetic-related industries through its subsidiary, IRAD
Corporation.
IRDC also is a manufacturer and distributor of cosmetics and skin
care products through its subsidiary, Carme, Inc. as well as
certain medical and health care products and services through
another of its subsidiaries, Medical Surgical Specialties, Ltd.
The common stock of International Research and Development
Corporation is traded in the over-the-counter national market.
The NASDAQ symbol for the common stock is IRDV.
